Hemoglobin gene therapy for β-thalassemia

Hematology/Oncology Clinics of North America

Volumn 24, Issue 6, 2010, Pages 1187-1201

  Bank, Arthur ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Clinical trials; Cooley anemia; Gene therapy; Lentiviruses; Thalassemia

Indexed keywords

BETA GLOBIN; HIGH MOBILITY GROUP A2 PROTEIN; LENTIVIRUS VECTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL TRIAL; GENE EXPRESSION; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENICS;

BETA-GLOBINS; BETA-THALASSEMIA; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENTIVIRUS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 78249246343     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.08.002     Document Type: Review

References (61)

1. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288(5466):669-672.
2. Cavazzana-Calvo M., Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet?. J Clin Invest 2007, 117(6):1456-1465.
3. Aiuti A., Cattaneo F., Galimberti S., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009, 360(5):447-458.
4. Kacian D., Spiegelman S., Bank A., et al. In vitro synthesis of DNA components of human genes for globins. Nat New Biol 1972, 235(58):167-169.
5. Verma I.M., Temple G.F., Fan H., et al. In vitro synthesis of DNA complementary to rabbit reticulocyte 10S RNA. Nat New Biol 1972, 235(58):163-167.
6. Grosveld F., van Assendelft G.B., Greaves D.R., et al. Position-independent, high-level expression of the human beta-globin gene in transgenic mice. Cell 1987, 51(6):975-985.
7. Hesdorffer C., Ayello J., Ward M., et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998, 16(1):165-172.
8. Abonour R., Williams D.A., Einhorn L., et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000, 6(6):652-658.
9. Markowitz D., Goff S., Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988, 167(2):400-406.
10. Markowitz D., Goff S., Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988, 62(4):1120-1124.
11. Dzierzak E.A., Papayannopoulou T., Mulligan R.C. Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 1988, 331(6151):35-41.
12. Gelinas R.E., Bender M.A., Miller A.D., et al. Long-term expression of the human beta-globin gene after retroviral transfer into pluripotent hematopoietic stem cells of the mouse. Adv Exp Med Biol 1989, 271:135-148.
13. Plavec I., Papayannopoulou T., Maury C., et al. A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood 1993, 81(5):1384-1392.
14. Raftopoulos H., Ward M., Leboulch P., et al. Long-term transfer and expression of the human beta-globin gene in a mouse transplant model. Blood 1997, 90(9):3414-3422.
15. May C., Rivella S., Callegari J., et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000, 406(6791):82-86.
16. Imren S., Payen E., Westerman K.A., et al. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A 2002, 99(22):14380-14385.
17. Imren S., Fabry M.E., Westerman K.A., et al. High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J Clin Invest 2004, 114(7):953-962.
18. Sadelain M. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr Opin Hematol 2006, 13(3):142-148.
19. Leboulch P., Huang G.M., Humphries R.K., et al. Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure. EMBO J 1994, 13(13):3065-3076.
20. Sadelain M., Wang C.H., Antoniou M., et al. Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. Proc Natl Acad Sci U S A 1995, 92(15):6728-6732.
21. Couzin J., Kaiser J. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow. Science 2005, 307(5712):1028.
22. Bank A., Dorazio R., Leboulch P. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann N Y Acad Sci 2005, 1054:308-316.
23. Anonymous Beta thalassemia treatment succeeds, with a caveat. Science 2009, 326:1468-1469.
24. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human thalassemia. Nature 2010;467:318-22.
25. Cockrell A.S., Ma H., Fu K., et al. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol Ther 2006, 14(2):276-284.
26. Cockrell A.S., Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol 2007, 36(3):184-204.
27. Broussau S., Jabbour N., Lachapelle G., et al. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther 2008, 16(3):500-507.
28. Throm R.E., Ouma A.A., Zhou S., et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 2009, 113(21):5104-5110.
29. Stewart H.J., Leroux-Carlucci M.A., Sion C.J., et al. Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. Gene Ther 2009, 16(6):805-814.
30. Ho C., Willis B.F., Shen T.J., et al. Roles of alpha 114 and beta 87 amino acid residues in the polymerization of hemoglobin S: implications for gene therapy. J Mol Biol 1996, 263(3):475-485.
31. De Angioletti M., Lacerra G., Pagano L., et al. Beta-thalassaemia-87 C→G: relationship of the Hb F modulation and polymorphisms in compound heterozygous patients. Br J Haematol 2004, 126(5):743-749.
32. Michlitsch J.G., Walters M.C. Recent advances in bone marrow transplantation in hemoglobinopathies. Curr Mol Med 2008, 8(7):675-689.
33. Lucarelli G., Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev 2008, 22(2):53-63.
34. Qin S., Ward M., Raftopoulos H., et al. Competitive repopulation of retrovirally transduced haemopoietic stem cells. Br J Haematol 1999, 107(1):162-168.
35. Wang G.P., Berry C.C., Malani N., et al. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood 2010, 115(22):4356-4366.
36. Sadelain M., Boulad F., Galanello R., et al. Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. Hum Gene Ther 2007, 18(1):1-9.
37. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326(5954):818-823.
38. Doetschman T., Gregg R.G., Maeda N., et al. Targetted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature 1987, 330(6148):576-578.
39. Templeton N.S., Roberts D.D., Safer B. Efficient gene targeting in mouse embryonic stem cells. Gene Ther 1997, 4(7):700-709.
40. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.
41. Takahashi K., Tanabe K., Ohnuki M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131(5):861-872.
42. Hanna J., Wernig M., Markoulaki S., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318(5858):1920-1923.
43. Wang Y., Nakayama N. WNT and BMP signaling are both required for hematopoietic cell development from human ES cells. Stem Cell Res 2009, 3(2-3):113-125.
44. Maherali N., Hochedlinger K. Tgfbeta signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Curr Biol 2009, 19(20):1718-1723.
45. Lin T., Ambasudhan R., Yuan X., et al. A chemical platform for improved induction of human iPSCs. Nat Methods 2009, 6(11):805-808.
46. Kim P.G., Daley G.Q. Application of induced pluripotent stem cells to hematologic disease. Cytotherapy 2009, 11(8):980-989.
47. Kaufman D.S. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 2009, 114(17):3513-3523.
48. Ichida J.K., Blanchard J., Lam K., et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009, 5(5):491-503.
49. Huang J., Chen T., Liu X., et al. More synergetic cooperation of Yamanaka factors in induced pluripotent stem cells than in embryonic stem cells. Cell Res 2009, 19(10):1127-1138.
50. Pestina T.I., Hargrove P.W., Jay D., et al. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther 2009, 17(2):245-252.
51. Bank A. Regulation of human fetal hemoglobin: new players, new complexities. Blood 2006, 107(2):435-443.
52. Sankaran V.G., Menne T.F., Xu J., et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008, 322(5909):1839-1842.
53. Sankaran V.G., Xu J., Ragoczy T., et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature 2009, 460(7259):1093-1097.
54. Lopez R.A., Schoetz S., DeAngelis K., et al. Multiple hematopoietic defects and delayed globin switching in Ikaros null mice. Proc Natl Acad Sci U S A 2002, 99(2):602-607.
55. Tulpule A., Daley G.Q. Efficient gene knockdowns in human embryonic stem cells using lentiviral-based RNAi. Methods Mol Biol 2009, 482:35-42.
56. Scherr M., Venturini L., Eder M. Knock-down of gene expression in hematopoietic cells. Methods Mol Biol 2009, 506:207-219.
57. Manjunath N., Wu H., Subramanya S., et al. Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev 2009, 61(9):732-745.
58. DelaFlor-Weiss E., Richardson C., Ward M., et al. Transfer and expression of the human multidrug resistance gene in mouse erythroleukemia cells. Blood 1992, 80(12):3106-3111.
59. Podda S., Ward M., Himelstein A., et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci U S A 1992, 89(20):9676-9680.
60. Allay J.A., Davis B.M., Gerson S.L. Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice. Exp Hematol 1997, 25(10):1069-1076.
61. Zhao H., Pestina T.I., Nasimuzzaman M., et al. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene. Blood 2009, 113(23):5747-5756.